- Home
- IXHL vs COEP Comparison
IXHL vs COEP Comparison
Compare IXHL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IXHL | COEP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IXHL | COEP |
|---|---|---|
| Price | $0.46 | $15.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.6M | 74.3K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $12,000.00 | ★ $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $2.31 |
| 52 Week High | $2.25 | $21.41 |
Technical Indicators
Market Signals| Indicator | IXHL | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 47.72 |
| Support Level | $0.35 | $15.40 |
| Resistance Level | $0.50 | $16.80 |
| Average True Range (ATR) | 0.03 | 1.57 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 80.58 | 20.64 |
Price Performance
Historical ComparisonAbout IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.